JP2023521384A - 活性化可能抗体を含む組成物 - Google Patents

活性化可能抗体を含む組成物 Download PDF

Info

Publication number
JP2023521384A
JP2023521384A JP2022561544A JP2022561544A JP2023521384A JP 2023521384 A JP2023521384 A JP 2023521384A JP 2022561544 A JP2022561544 A JP 2022561544A JP 2022561544 A JP2022561544 A JP 2022561544A JP 2023521384 A JP2023521384 A JP 2023521384A
Authority
JP
Japan
Prior art keywords
composition
activatable antibody
less
intact
hcp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521384A5 (enExample
Inventor
パトリック，サラ
クレッバー，クラウス
ヴィスワナサン，スリッダー
ゴネラ ドゥーバー，シャンティ
ウレノ，エリック
Original Assignee
シートムエックス セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シートムエックス セラピューティクス，インコーポレイテッド filed Critical シートムエックス セラピューティクス，インコーポレイテッド
Publication of JP2023521384A publication Critical patent/JP2023521384A/ja
Publication of JP2023521384A5 publication Critical patent/JP2023521384A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022561544A 2020-04-09 2021-04-09 活性化可能抗体を含む組成物 Pending JP2023521384A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063007776P 2020-04-09 2020-04-09
US63/007,776 2020-04-09
PCT/US2021/026661 WO2021207657A1 (en) 2020-04-09 2021-04-09 Compositions containing activatable antibodies

Publications (2)

Publication Number Publication Date
JP2023521384A true JP2023521384A (ja) 2023-05-24
JP2023521384A5 JP2023521384A5 (enExample) 2024-04-19

Family

ID=75747125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561544A Pending JP2023521384A (ja) 2020-04-09 2021-04-09 活性化可能抗体を含む組成物

Country Status (11)

Country Link
US (2) US12428470B2 (enExample)
EP (1) EP4132656A1 (enExample)
JP (1) JP2023521384A (enExample)
KR (1) KR20220166814A (enExample)
CN (1) CN115427113A (enExample)
AU (1) AU2021254279A1 (enExample)
BR (1) BR112022019841A2 (enExample)
CA (1) CA3174665A1 (enExample)
IL (1) IL296634A (enExample)
MX (1) MX2022011780A (enExample)
WO (1) WO2021207657A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250333539A1 (en) 2022-03-23 2025-10-30 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
JP2025512798A (ja) 2022-03-25 2025-04-22 サイトムエックス セラピューティクス，インク． 活性化可能な二重アンカー型マスク化分子及びその使用方法
WO2023192973A1 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
EP4504782A2 (en) 2022-04-01 2025-02-12 CytomX Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
US20260049148A1 (en) 2022-08-01 2026-02-19 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
EP4565250A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
US20260015425A1 (en) 2022-08-01 2026-01-15 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
AR130080A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Restos escindibles por proteasas, y métodos de uso de los mismos
EP4565260A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
WO2024216194A1 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
JP2026513839A (ja) 2023-04-12 2026-05-01 サイトムエックス セラピューティクス，インク． マスキングポリペプチド、活性化可能サイトカイン構成体、ならびに関連する組成物及び方法
WO2025015060A1 (en) * 2023-07-11 2025-01-16 Brave Bio, Inc. Engineered vectorized antibodies with reduced stability in systemic circulation and uses thereof
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
WO2026035650A2 (en) 2024-08-05 2026-02-12 Cytomx Therapeutics, Inc. Cleavable polypeptides and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516813A (ja) * 2012-04-27 2015-06-18 シトムクス セラピューティクス，インコーポレイティド 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法
WO2019108733A2 (en) * 2017-12-01 2019-06-06 Seattle Genetics, Inc. Cd47 antibodies and uses thereof for treating cancer
WO2019149281A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2020252264A1 (en) * 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454715B (sv) 1986-09-29 1988-05-24 Gkn Stenman Ab Tryckeselement
JPH0517595A (ja) 1991-07-15 1993-01-26 Matsushita Electric Ind Co Ltd 高分子超薄膜エレクトレツト及びその製造方法
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
US7354740B2 (en) 2003-09-25 2008-04-08 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
DE602004026343D1 (de) 2003-10-24 2010-05-12 Amgen Inc Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
US7541330B2 (en) * 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
US20060088522A1 (en) * 2004-09-10 2006-04-27 Wyeth Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugates
SG156672A1 (en) 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
WO2006122424A1 (en) * 2005-05-19 2006-11-23 Caprion Pharmaceuticals Inc. Protein depletion using volatile binding buffers
EP2535346B1 (en) 2005-08-31 2017-08-02 The Regents of The University of California Cellular libraries of peptide sequences (CLiPS) and methods of using the same
CA2645347A1 (en) 2006-03-10 2007-09-20 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
EP2738179A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
WO2010081173A2 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
RU2013110876A (ru) 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9249182B2 (en) * 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
SG11201408554QA (en) 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
US9856314B2 (en) 2012-06-22 2018-01-02 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and methods of using the same
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
EP2934603A1 (en) 2012-12-20 2015-10-28 Omrix Biopharmaceuticals Ltd. Viral inactivated biological mixture
CA2896282C (en) 2013-01-04 2021-07-20 Cytomx Therapeutics, Inc. Compositions and methods for detecting protease activity in biological systems
CN105324393A (zh) * 2013-05-13 2016-02-10 米迪缪尼有限公司 具有最小单体分离的重组多克隆抗体多聚体的分离
BR112015030514A2 (pt) 2013-06-04 2017-08-29 Cytomx Therapeutics Inc Composições e métodos para conjugação de anticorpos ativáveis
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
KR102488220B1 (ko) 2013-09-25 2023-01-12 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
KR102466591B1 (ko) 2014-01-31 2022-11-14 싸이톰스 테라퓨틱스, 인크. 마트립타제 및 ｕ-플라스미노겐 활성화인자 기질 및 다른 절단성 모이어티 및 이의 사용 방법
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016046778A2 (en) 2014-09-25 2016-03-31 Amgen Inc Protease-activatable bispecific proteins
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
SG10202005917SA (en) 2015-03-06 2020-07-29 Genentech Inc Ultrapurified dsba and dsbc and methods of making and using the same
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
HK1250997A1 (zh) 2015-05-01 2019-01-18 基因泰克公司 掩蔽抗cd3抗体和使用方法
US10233244B2 (en) 2015-05-04 2019-03-19 Cytomx Therapeutics, Inc. Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
SG10202110908WA (en) 2015-05-04 2021-11-29 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
IL310251A (en) 2015-05-04 2024-03-01 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof
WO2016182064A1 (ja) 2015-05-13 2016-11-17 中外製薬株式会社 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
WO2017025698A1 (en) 2015-08-11 2017-02-16 Queen Mary University Of London Bispecific, cleavable antibodies
CA3013479A1 (en) 2016-02-16 2017-08-24 Carl NOVINA Immunotherapy compositions and methods
TW202302631A (zh) 2016-03-08 2023-01-16 日商武田藥品工業股份有限公司 可誘導性結合蛋白和使用方法
MA43724B1 (fr) 2016-03-22 2023-06-28 Hoffmann La Roche Molécules bispécifiques de cellules t activées par une protéase
TWI762487B (zh) 2016-06-08 2022-05-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
EP3468598A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
AU2017277534A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-EGFR antibody drug conjugates
EP3442988A4 (en) 2016-06-15 2020-02-26 Agency for Science, Technology and Research METHOD FOR IMPROVING THE PERFORMANCE OF CHROMATOGRAPHY PROCESSES FOR THE PURIFICATION OF PROTEINS
CN114749162B (zh) 2016-07-14 2025-04-08 思拓凡生物工艺研发有限公司 包含聚合物纳米纤维的官能化色谱介质及其制备方法
KR102435801B1 (ko) 2016-07-22 2022-08-25 암젠 인크 Fc-함유 단백질의 정제 방법
US10688412B2 (en) * 2016-07-25 2020-06-23 Cehpalon, Inc. Affinity chromatography wash buffer
JP2019530646A (ja) 2016-08-12 2019-10-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質精製法
KR20230041834A (ko) 2016-08-16 2023-03-24 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
US11155794B2 (en) 2016-08-23 2021-10-26 Alexion Pharmaceuticals, Inc. Method of purifying a heterologous protein from an egg white
US11519851B2 (en) 2016-09-17 2022-12-06 C Technologies Inc. Monitoring of compounds
BR112019008223A2 (pt) * 2016-11-03 2019-07-16 Bristol-Myers Squibb Company anticorpos anti-ctla-4 ativáveis e usos dos mesmos
WO2019018828A1 (en) * 2017-07-20 2019-01-24 Cytomx Therapeutics, Inc. METHODS OF QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ACTIVATABLE ANTIBODY PROPERTIES AND USES THEREOF
BR112020007302B1 (pt) 2017-10-14 2023-01-31 Abbvie Inc. Anticorpos ativáveis conjugados anti-cd71, método para fabrica-los, composição farmacêutica e kit que compreende os mesmos, usos dos ditos anticorpos, bem como método in vitro para detectar a presença ou ausência do agente de clivagem na amostra
TW202600611A (zh) * 2017-11-01 2026-01-01 日商中外製藥股份有限公司 生物活性降低之抗體變異體與同功型
MX2020008095A (es) * 2018-01-31 2020-09-24 Regeneron Pharma Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
WO2019165143A1 (en) * 2018-02-21 2019-08-29 Cytomx Therapeutics, Inc. Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof
WO2020247574A1 (en) * 2019-06-05 2020-12-10 Seattle Genetics, Inc. Methods of purifying masked antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516813A (ja) * 2012-04-27 2015-06-18 シトムクス セラピューティクス，インコーポレイティド 上皮成長因子受容体を結合する活性化可能抗体及びその使用方法
WO2019108733A2 (en) * 2017-12-01 2019-06-06 Seattle Genetics, Inc. Cd47 antibodies and uses thereof for treating cancer
WO2019149281A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2020252264A1 (en) * 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CHROMATOGRAPHY A, vol. 1602, JPN6025026554, 2019, pages 317 - 325, ISSN: 0005765054 *
PROTEIN EXPRESSION AND PURIFICATION, vol. 167, no. 105529, JPN6025026552, March 2020 (2020-03-01), pages 1 - 10, ISSN: 0005765053 *

Also Published As

Publication number Publication date
EP4132656A1 (en) 2023-02-15
US12428470B2 (en) 2025-09-30
US20210317188A1 (en) 2021-10-14
CN115427113A (zh) 2022-12-02
CA3174665A1 (en) 2021-10-14
AU2021254279A1 (en) 2022-11-10
US20250382351A1 (en) 2025-12-18
WO2021207657A9 (en) 2021-12-16
KR20220166814A (ko) 2022-12-19
MX2022011780A (es) 2022-11-10
IL296634A (en) 2022-11-01
BR112022019841A2 (pt) 2022-12-06
WO2021207657A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
US12428470B2 (en) Compositions containing activatable antibodies
JP7462560B2 (ja) 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法
WO2023015169A1 (en) Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
CA3251000A1 (en) METHODS FOR PURIFYING A PRODUCT
JP2010516651A (ja) Ｆｃ含有タンパク質の精製のための方法
JP7777988B2 (ja) 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法
US20250277051A1 (en) Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
US20230265406A1 (en) Recombinant sialidases with reduced protease sensitivity, sialidase fusion proteins, and methods of using the same
WO2022081794A1 (en) Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof
US20240067729A1 (en) Anti-pd-l1 antibodies and fusion proteins thereof
US20250333539A1 (en) Activatable antigen-binding protein constructs and uses of the same
AU2020298628A1 (en) Sialidase-CD20-antibody fusion proteins and methods of use thereof
WO2025217138A1 (en) Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
IL314373A (en) ANTI-BTLA antibodies and their use for cancer treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240409

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406